Previous 10 | Next 10 |
Pharmaceutical stocks were initially expected to be largely immune to the COVID-19 economic downturn. Drugmakers, after all, generally produce products that are essential to daily life. However, the extreme social distancing that has become part and parcel of this unusual period has halted nume...
Agenus (AGEN) offered a bundle of encouraging data readouts on March 12, 2020. These included FDA Fast Track designation for the balstilimab plus zalifrelimab combination therapy, improved efficacy data for the combination, improved early indicators for AGEN1181, and a milestone payment based ...
Image source: The Motley Fool. Agenus Inc (NASDAQ: AGEN) Q4 2019 Earnings Call Mar 12, 2020 , 8:30 a.m. ET Operator Continue reading
Start Time: 08:30 End Time: 09:14 Agenus Inc. (AGEN) Q4 2019 Earnings Conference Call March 12, 2020, 08:30 AM ET Company Participants Garo Armen - Chairman and CEO Jennifer Buell - President and COO Christine Klaskin - VP, Finance and Principal Accounting Officer Conferen...
The following slide deck was published by Agenus Inc. in conjunction with their 2019 Q4 earnings Read more ...
The FDA designates Agenus' ( AGEN -6% ) combination of PD-1 inhibitor balstilimab and CTLA-4 inhibitor zalifrelimab for Fast Track review for the treatment of relapsed/refractory metastatic cervical cancer. More news on: Agenus Inc., Healthcare stocks news, Stocks on the move, ...
Agenus ( AGEN ) Q4 results : More news on: Agenus Inc., Healthcare stocks news, Earnings news and commentary, Read more ...
LEXINGTON, Mass. , March 12, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track des...
Agenus (NASDAQ: AGEN ): Q4 GAAP EPS of -$0.22 beats by $0.16 . More news on: Agenus Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
LEXINGTON, Mass. , March 12, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of agents designed to activate immune response to cancers provided a corporate update and reported financial results for the fourth quarter and full yea...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...